Skip to main content
36°
Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Cue Biopharma, Inc. - Common Stock
(NQ:
CUE
)
1.010
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 12, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
1.010
Bid (Size)
0.5447 (10)
Ask (Size)
1.610 (2)
Prev. Close
1.010
Today's Range
1.010 - 1.010
52wk Range
0.4500 - 2.260
Shares Outstanding
44,959,548
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Cue Biopharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 29, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Participate in Fireside Discussion at the Piper Sandler 36th Annual Healthcare Conference
November 25, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Performance
YTD
-7.34%
-7.34%
1 Month
-24.06%
-24.06%
3 Month
-7.34%
-7.34%
6 Month
+71.36%
+71.36%
1 Year
-42.94%
-42.94%
More News
Read More
Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 14, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Strategic Organizational Transition
November 14, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Participate in Fireside Chat at the Stifel 2024 Healthcare Conference
November 12, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Presents Positive Updated Data from its Phase 1 Trials of CUE-101 and CUE-102 in Head and Neck Cancer and WT1 Positive Cancers at the SITC 39th Annual Meeting
November 08, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
October 11, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
October 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
October 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
October 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
October 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
October 04, 2024
Via
Benzinga
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
October 04, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
October 03, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
September 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
September 27, 2024
Via
Benzinga
Cue Biopharma Announces Pricing of $12.0 Million Public Offering
September 26, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Announces Proposed Public Offering
September 26, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
September 26, 2024
Via
Benzinga
Cue Biopharma Announces Proposed Public Offering
September 26, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Appoints Industry Veteran Lucinda Warren as Chief Business Officer
September 09, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma to Present at The Promise of Interleukin-2 Therapy Conference
September 03, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
Cue Biopharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 19, 2024
From
Cue Biopharma, Inc.
Via
GlobeNewswire
CUE Stock Earnings: Cue Biopharma Beats EPS, Beats Revenue for Q2 2024
August 15, 2024
Via
InvestorPlace
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.